NCT05955196 (MACROSWITCH) is a clinical trial of BLOOD AND TUMOR in Cancer of the Colon, sponsored by Institut Paoli-Calmettes.

Who is sponsoring NCT05955196?

NCT05955196 is sponsored by Institut Paoli-Calmettes.

What drugs are being tested in NCT05955196?

Interventions in NCT05955196: BLOOD AND TUMOR.

What condition does NCT05955196 study?

NCT05955196 studies Cancer of the Colon.

Is NCT05955196 still recruiting?

NCT05955196 is currently recruiting now. Last updated 9 October 2024.

Last reviewed 2024-10-09 · How we verify

NCT05955196: MACROSWITCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer

Recruiting now Last updated 9 October 2024

What this trial tests

trial testing BLOOD AND TUMOR in Cancer of the Colon in 115 participants. Currently enrolling.

Timeline

9 January 2023

Primary endpoint
9 January 2025

9 January 2027

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	115
Start date	9 January 2023
Primary completion	9 January 2025
Estimated completion	9 January 2027
Sites	1 location across France

Drugs / interventions tested

BLOOD AND TUMOR

Conditions studied

Cancer of the Colon — all drugs for Cancer of the Colon →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

18 and older, any sex, with Cancer of the Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. . In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
The role of macrophages in gastric cancer.
Zhang J, Hu C, Zhang R, Xu J, et al · · 2023 · cited 16× · PMID 38143746 · DOI 10.3389/fimmu.2023.1282176
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges.
Wang Y, Zhang L, Wang LZ, Cao Y, et al · · 2025 · cited 4× · PMID 40855314 · DOI 10.1186/s12943-025-02429-0
Immune organoid for cancer immunotherapy.
Wang XH, Wang WY, Sun ZJ. · · 2025 · cited 2× · PMID 40698131 · DOI 10.1016/j.apsb.2025.04.031
Integrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery.
Patra D, Sayed IM, Mukherjee S, Piplani H, et al · · 2026 · PMID 41766415 · DOI 10.1002/advs.202522276
Advances in precision oncology using patient-derived organoids and functional biomaterials.
Singh H, Mijakovic I, Singh P. · · 2025 · PMID 41098309 · DOI 10.3389/fcell.2025.1670328

Verify or expand the search:

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05955196 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 9 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05955196.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing